December 6, 2007 - Boston Scientific Corp. welcomed the recommendation of a FDA advisory panel to approve with conditions the PROMUS/ XIENCE V everolimus-eluting coronary stent system, marking a significant step toward making Boston Scientific's two-drug program a reality in the U.S.
The PROMUS and XIENCE V stent systems are identical products, sold respectively by Boston Scientific and Abbott in international markets. Both stent systems would be covered by the same FDA approval.
